News | May 01, 2015

Frost and Sullivan Names Toshiba Company of the Year

Toshiba’s value-based business model enables customers to leverage their vendor organization as a growth partner

Based on its ongoing analysis of the medical imaging market, Frost & Sullivan recognizes Toshiba America Medical Systems, Inc. with the 2015 North American Frost & Sullivan Award for Medical Imaging Company of the Year. The company has changed the way it approaches the imaging market by offering scalable, upgradable technologies and a patient-focused view of partnerships. This value-based approach positions the company for continued success in the medical imaging market by allowing it to re-orient many of its imaging customers away from a cyclical sales model and toward deeper, more renewable strategic partnerships.

Toshiba’s partnership approach is proving highly beneficial for its customers, while also providing the company with a solid outlet for the premium products and technologies across its medical imaging portfolio.

“Toshiba’s move toward establishing value as the foundation of the organization is a massive undertaking, involving the restructuring, training and education of internal teams across business units—all the way from R&D to customer support,” said Frost & Sullivan industry principal Nadim Daher. “The company has acknowledged value as a Mega Trend and has prioritized aligning its business model with the evolution of customers’ purchasing processes.”

The company’s consultative go-to-market strategy allows it to offer customized single-modality or multi-modality solutions, typically mixing of premium and value imaging systems along with value-add services, such as tailored education and training. It enhances the overall purchase experience for customers with greater flexibility in pricing, deployment and service models. This helps it compete as a best-of-breed vendor and a single vendor in the modalities of computed tomography (CT), magnetic resonance (MR), interventional and diagnostic X-ray, ultrasound, and positron emission tomography (PET).

As customers for its cross-modality offerings continue to increase, Toshiba is focusing internally on developing new synergies across its product lines by investing in transversal technologies. For instance, the technology behind the innovative Dose Tracking System (DTS) that it introduced for the angiography X-ray product line can be leveraged in other radiation-emitting modalities, such as CT.

Another example of Toshiba’s market growth is its recent entry into the U.S. molecular imaging market through the introduction of the new Food and Drug Administration (FDA)-cleared Celesteion PET-CT system. This homegrown solution considerably enhances Toshiba’s value proposition for the oncology imaging specialty, one of the most solid growth areas for imaging, and complements it dominance in other specialties, such as cardiovascular and radiology imaging.

“Importantly, Toshiba’s brand equity is rising in the marketplace among both departmental and enterprise-level customers, thereby encompassing various stakeholders in large-scale medical imaging investments,” observed Daher. “More provider organizations are choosing Toshiba, as the company goes beyond the role of supplier and partners with them to help them achieve their business goals.”

Overall, for its higher value proposition, customer benefits, market leadership, and implementation of best practices, Toshiba America Medical Systems is a deserving recipient of Frost & Sullivan’s 2015 North American Company of the Year Award.

Each year, Frost & Sullivan presents this award to the company that has demonstrated excellence in terms of growth strategy and implementation. The award recognizes a high degree of innovation with products and technologies, and the resulting leadership in terms of customer value and market penetration.

Frost & Sullivan’s Best Practices Awards recognize companies in a variety of regional and global markets for outstanding achievement in areas such as leadership, technological innovation, customer service, and product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research.

For more information: www.medical.toshiba.com.

 

Related Content

The Clear AI software can help with identification coronary plaque features in CT scans that may cause heart attacks. Cleerly Coronary’s noninvasive, AI-driven approach supports the understanding of plaques using FDA-cleared technologies.

The Clear AI software can help with identification coronary plaque features in CT scans that may cause heart attacks. Cleerly Coronary’s noninvasive, AI-driven approach supports the understanding of plaques using FDA-cleared technologies.

News | Computed Tomography (CT) | July 16, 2021
July 16, 2021 — Canon Medical Systems USA is joining forces with Cleerly in a strategic partnership to support simple
The inherent spectral capabilities of Mayo Clinic's new third-generation photon-counting CT research scanner allows clear visualization of the intact portions of the coronary artery lumen (arrowhead) by reducing the bright signal from the dense coronary calcifications (arrows). Spectral CT is able to bin photos on different energies that can be used to enhance or subtract chemical elements based on their spectral signature, such as calcium shown here, and iodine.

The inherent spectral capabilities of Mayo Clinic's new third-generation photon-counting CT research scanner allows clear visualization of the intact portions of the coronary artery lumen (arrowhead) by reducing the bright signal from the dense coronary calcifications (arrows). Spectral CT is able to bin photos on different energies that can be used to enhance or subtract chemical elements based on their spectral signature, such as calcium shown here, and iodine.
 

News | Computed Tomography (CT) | July 14, 2021
July 14, 2021 — Performing the first cardiac scan on their new photon-counting detector...
Illustration of how spectral CT can help confirm findings on a conventional CT scan without requiring follow-up imaging, such as a nuclear scan. The conventional CT on the left, and the dual-energy CT on the right confirms an infarct.

Illustration of how spectral CT can help confirm findings on a conventional CT scan without requiring follow-up imaging, such as a nuclear scan. The conventional CT on the left, and the dual-energy CT on the right confirms an infarct. Image from Philips Healthcare.

Feature | Computed Tomography (CT) | May 27, 2021
May 27, 2021 — Philips Healthcare released a workhorse...
FDA Clears AiCE Image Reconstruction on Canon's Aquilion Precision CT
Technology | Computed Tomography (CT) | October 21, 2019
Canon Medical Systems USA Inc. has received U.S. Food and Drug Administration (FDA) 510(k) clearance on its Advanced...
FDA Clears Modules of AI-Rad Companion Chest CT From Siemens Healthineers
Technology | Computed Tomography (CT) | September 26, 2019
The U.S. Food and Drug Administration (FDA) has cleared three modules of AI-Rad Companion Chest CT, an intelligent...
Videos | Computed Tomography (CT) | August 07, 2019
This is an example of in-stent restenosis shown using spectral CT imaging.
Achenbach to Receive Inaugural 2019 Stephan Achenbach Pioneer Award in Cardiovascular CT
News | Computed Tomography (CT) | July 10, 2019
The Society of Cardiovascular Computed Tomography (SCCT) will present Stephan Achenbach, M.D., FSCCT with the inaugural...
New Type of Cardiac Care to Cut Imaging Wait Times and Unnecessary Hospital Admissions
News | Computed Tomography (CT) | June 20, 2019
A new type of care for cardiac patients at St. Paul’s Hospital, Vancouver, has the potential to reduce heart imaging...
Canon Medical Receives FDA Clearance for AiCE Reconstruction Technology for CT
Technology | Computed Tomography (CT) | June 18, 2019
Canon Medical Systems USA Inc. has received 510(k) clearance on its new deep convolutional neural network (DCNN) image...